5-amino-1MQ for fat loss: what the science actually says

What did @felixgaray6 actually say?

Honestly, very little that's coherent. The transcript is almost entirely garbled, likely the result of faulty auto-captioning or a translation error from Spanish. The caption claims 5-amino-1MQ is "el peptido para oxidar grasa" — the peptide for oxidizing fat — but the spoken content that was captured is functionally incoherent, mixing English fragments about viruses, cancer, and something called "Scarra" with what appears to be a Spanish sign-off about supplements.

What we can evaluate is the core caption claim: that 5-amino-1MQ is a fat-oxidizing peptide worth your attention. That framing, while popular in biohacking circles, deserves real scrutiny. The compound is real. The hype around it is running well ahead of the evidence.

Does the science back this up?

Partially, but only in early-stage animal research. 5-amino-1MQ is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that regulates cellular metabolism. The argument is that inhibiting NNMT raises NAD+ levels and shifts fat cells toward burning energy rather than storing it. That mechanism is biologically plausible. The data, however, is thin.

The most-cited work comes from Hong et al. (2015, Biochemical and Biophysical Research Communications), showing NNMT inhibition in mice reduced fat mass and improved metabolic markers. Kilgour et al. (2021, Journal of Medicinal Chemistry) followed with more refined NNMT inhibitors including 5-amino-1MQ analogs, again in rodent models. No published randomized controlled trials in humans exist as of early 2025. Calling it a proven fat-oxidizing peptide, as the caption does, skips several critical steps in the research pipeline. It is also worth noting that 5-amino-1MQ is technically a small molecule, not a peptide, which is a basic categorization error.

What did they get wrong (or right)?

The caption calling 5-amino-1MQ a "peptido" (peptide) is simply incorrect. A peptide is a chain of amino acids. 5-amino-1MQ is a methylquinolinium derivative, a small organic molecule. This is not a trivial distinction. It affects how the compound is regulated, how it's absorbed, and how it should be discussed clinically. Getting that wrong at the top of a 12,000-view post is a meaningful error.

What they got directionally right is that NNMT inhibition has legitimate scientific interest as a metabolic target. Researchers are genuinely exploring this pathway. But "has interesting preclinical data" and "oxidizes fat" are very different claims. The first is defensible. The second implies a human benefit that hasn't been demonstrated in controlled trials. Framing it as settled science to a fitness audience is misleading, even if the underlying biology is interesting.

• 5-amino-1MQ is not a peptide. It is a small molecule NNMT inhibitor.
• Human clinical trial data does not currently exist for this compound.
• Animal studies show metabolic effects, but rodent metabolism does not always translate to humans.

What should you actually know?

If you've seen 5-amino-1MQ circulating in peptide and biohacking communities, you're not imagining it. Interest in NNMT inhibition is real, and some compounding pharmacies do offer this compound. But the gap between "interesting mouse study" and "safe and effective for human fat loss" is enormous, and nobody has crossed it yet with rigorous human data.

The safety profile in humans is not established. Long-term effects of NNMT inhibition are unknown. NNMT plays roles beyond fat metabolism, including in cancer biology, which makes indiscriminate inhibition a research question, not a recommendation. Anyone considering this compound should be doing so under medical supervision, not because a TikTok caption told them it burns fat. The compound may eventually prove useful. Right now, it is an experimental molecule with preclinical promise and no human trial record.